Log In
BCIQ
Print this Print this
 

OQR200

  Manage Alerts
Collapse Summary General Information
Company OncoQR ML
DescriptionSpecific T-cell immune remodeling (S-TIR) active immunotherapy against EGFR2
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of Action 
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsTreat breast cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today